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Abstract
Regulators of G Protein Signaling (RGS proteins) inhibit G protein-coupled receptor
(GPCR) signaling by accelerating the GTP hydrolysis rate of activated Gα subunits. Some
RGS proteins exert additional signal modulatory functions, and RGS12 is one such protein,
with five additional, functional domains: a PDZ domain, a phosphotyrosine-binding domain,
two Ras-binding domains, and a Gα�GDP-binding GoLoco motif. RGS12 expression is tem-
porospatially regulated in developing mouse embryos, with notable expression in somites
and developing skeletal muscle. We therefore examined whether RGS12 is involved in the
skeletal muscle myogenic program. In the adult mouse, RGS12 is expressed in the tibialis
anterior (TA) muscle, and its expression is increased early after cardiotoxin-induced injury,
suggesting a role in muscle regeneration. Consistent with a potential role in coordinating
myogenic signals, RGS12 is also expressed in primary myoblasts; as these cells undergo
differentiation and fusion into myotubes, RGS12 protein abundance is reduced. Myoblasts
isolated from mice lacking Rgs12 expression have an impaired ability to differentiate into
myotubes ex vivo, suggesting that RGS12 may play a role as a modulator/switch for differ-
entiation. We also assessed the muscle regenerative capacity of mice conditionally deficient
in skeletal muscle Rgs12 expression (via Pax7-driven Cre recombinase expression), follow-
ing cardiotoxin-induced damage to the TA muscle. Eight days post-damage, mice lacking
RGS12 in skeletal muscle had attenuated repair of muscle fibers. However, when mice lack-
ing skeletal muscle expression of Rgs12 were cross-bred with mdx mice (a model of human
Duchenne muscular dystrophy), no increase in muscle degeneration was observed over
time. These data support the hypothesis that RGS12 plays a role in coordinating signals
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Introduction
Regulators of G protein Signaling (RGS proteins) are intracellular GTPase-accelerating pro-
teins (GAPs) that attenuate the G protein-dependent signals that cells receive from their exter-
nal environment [1, 2]. The RGS protein family member RGS12 is unique in interacting with
multiple signaling pathways, including those associated with growth and survival cues from
receptor tyrosine kinases (RTKs) and mitogen-activated protein kinases (MAPKs), G protein-
coupled receptors (GPCRs), and Ras GTPases [3–9]. It was previously reported that skeletal
muscles of developing mouse embryos express RGS12 [10], suggesting a potential role for this
unique RGS family member in the skeletal muscle developmental process; however, little has
since been reported regarding potential function(s) of RGS12 in the signaling pathways under-
lying the myogenesis program active during both development and muscle repair. With
regards to the latter, adult skeletal muscle has a remarkable regenerative capacity, largely made
possible by a specialized population of stem cells—satellite cells—found in a characteristic
niche between the sarcolemma and basal lamina of myofibers [11–13]. Myogenesis requires
strictly regulated signaling events involving the activation (and subsequent proliferation) of
quiescent satellite cells, expression of muscle-specific genes, and differentiation into new mus-
cle fibers during repair or fusion into existing fibers during growth [14]. Muscle regeneration
begins with satellite cell activation by alterations to their niche and by factors released during
injury, resulting in MYF5 and MYOD induction and several cycles of proliferation. Although
some activated satellite cells remain in their niche and return to quiescence as a reservoir,
other daughter cells migrate along the sarcolemma then differentiate and fuse with either dam-
aged fibers or with other myoblasts to form repaired or de novo myofibers, respectively. This
process is characterized by PAX7 down-regulation and up-regulation of muscle-specific genes
(e.g., MRF4, myogenin) [15].
Myogenesis during both embryonic development and adult muscle regeneration shares
many regulatory mechanisms [12], including signals from sequential MAPK activation [16].
PAX7-positive satellite cells are constitutively active during embryonic development, but these
cells exit the cell cycle during adulthood and become quiescent [17]. External stimuli, such as
serum and certain growth factors, can activate satellite cells and promote proliferation by sig-
naling through various MAPK pathways, including extracellular-signal related kinase (ERK1/
2) activity [18]. In cultured myoblasts, the onset of differentiation by serum deprivation trig-
gers a decline in ERK1/2 activity [19, 20]. Myoblast differentiation is inhibited by serum and
certain growth factors known to activate the small GTPase H-Ras [21, 22]. Various mutations
in human rhabdomyosarcoma cell lines (e.g., RD cells) typically cause an inability to differenti-
ate in response to serum deprivation; multiple mutations in RD cells, including mutation of
the NRAS gene [23], impair differentiation. Similarly, expression of oncogenic (constitutively-
active) H-Ras in myoblasts prevents myotube formation and blocks induction of myogenic
genes and muscle-regulatory factors, such as MyoD1 and myogenin [24–26].
As the ERK1/2 MAPK cascade is activated by many stimuli, multiple mechanisms exist to
ensure specific and appropriate biological outcomes, particularly in such a highly temporally
regulated process as myogenesis [27, 28]. In this regard, scaffold proteins play an important
role by spatially focusing MAPK signaling in many cell systems [29, 30]. RGS12 shares features
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with such MAPK scaffolds, containing two Ras-binding domains and a GoLoco motif, the lat-
ter being a second Gαi binding site that inhibits nucleotide release [31] and facilitates endoso-
mal targeting [6]. RGS12 also has PDZ and PTB domains, each of which promotes additional
protein-protein interactions. As previously reported [7], RGS12 uses these latter two domains
to interact with multiple components of the Ras/Raf/MEK/ERK1/2 signaling cascade. Here,
we employed genetic manipulations of both the C2C12 myoblastic cell line and the mouse
genome to investigate the role of RGS12 and its MAPK scaffolding function in the signaling
that balances myoblast proliferation versus differentiation, both in vitro and in vivo. Our pres-
ent studies utilized two, recently described strains of RGS12-deficient mice: namely, constitu-
tive Rgs12Δ5-8/Δ5–8 and Cre recombinase-dependent Rgs12Δ5-6/Δ5–6 knockout strains [32].
Materials and methods
Materials
pLKO.1 plasmids encoding mouse Rgs12-directed shRNA (IDs TRCN0000037205 [“#2”] and
TRCN0000037208 [“#5”]; generated by The RNAi Consortium and purchased from Open Bio-
systems) were prepared from bacterial stocks via plasmid DNA maxiprep (Qiagen; Valencia,
CA) and packaged as lentiviridae by the UNC Lineberger Lenti-shRNA Core Facility (Dr. Tal
Kafri, director). A control empty lentiviral vector (Open Biosystems catalog #RHS4080) was
also packaged to establish negative control cell lines. GFP-tagged Cre recombinase- or GFP-
transducing (negative control) adeno-associated viruses (AAV1.CMV.HI.GFP-Cre.WPRE.
SV40 and AAV1.CMV.PI.EGFP.WPRE.bGH, respectively) were purchased from the U. Penn.
Virology Core Facility (Philadelphia, PA). Myc-H-Ras(G12V) expression vector was a kind
gift from Dr. Channing Der (UNC-Chapel Hill). Cardiotoxin (CTX) from Naja mossambica
mossambica (Sigma-Aldrich) was dissolved in sterile saline to a final concentration of 10 μM
and aliquoted and stored at –20˚C. Anti-RGS12 (UNC60-80.4.1 and UNC60-26.2.1; each used
at 1:1000 dilution), anti-Pax7 (PAX7; 1:100), anti-myogenin (PCRP-MYOG-1C5; 1:1000), and
anti-MHC (MF 20; 1:1000) antibodies were each obtained from the Developmental Studies
Hybridoma Bank (Iowa City, Iowa); anti-APPL1 (H-96/sc-67402; 1:500), anti-GAPDH (sc-
32233; 1:2000), and anti-Rab9 (G-5/sc-74482; 1:800) antibodies were procured from Santa
Cruz Biotechnology Inc (Santa Cruz, CA). Antibodies directed toward cyclophilin A (#2175;
1:1000), total ERK1/2 (p44/42 MAPK; #9102; 1:1000), and phosphorylated ERK1/2 (Thr202/
Tyr204; #9101; 1:1000) were obtained from Cell Signaling Technology. Anti-FLAG-epitope
(F3165; 1:2000), anti-β-tubulin (T8328; 1:5000), and anti-β-actin (A5441; 1:4000) antibodies
were purchased from Sigma-Aldrich; anti-HA-epitope antibody (12CA5; 1:2000) and anti-
Myc-epitope antibody (9E10; 1:4000) were obtained from Roche. Anti-H-Ras antibody 146-
3E4 from Quality Biotech (Camden, NJ) was a kind gift from Dr. Adrienne Cox (UNC-Chapel
Hill) and used at 1:1000 in immunoblotting. Anti-Myf5 antibody (MABE485; 1:1000) was
obtained from Millipore. Wheat germ agglutinin (WGA) conjugated to Alexa fluor-488 (Invi-
trogen) was dissolved in PBS, aliquoted, and stored at -20˚C. Two cell lines were obtained
from the American Type Culture Collection (ATCC; Manassas, VA): the C2C12 adherent
myoblastic cell line (ATCC CRL-1772) derived from a C3H mouse; and, the RD adherent cell
line (ATCC CCL-136) derived from a rhabdomyosarcoma of a 7-year-old female Caucasian
and exhibiting an unstable karyotype (i.e., hyperdiploid with a bimodal stemline number of
49 and 50 chromosomes). Precast Tris-glycine SDS-PAGE gels and ancillary reagents/buffers
for immunoblotting were obtained from Novex/Invitrogen. Unless elsewhere specified, all
additional reagents were of the highest quality obtainable from Fisher Scientific (Pittsburgh,
PA).
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Animals
Generation of two independent strains of Rgs12-deficient mice (constitutive Rgs12Δ5-8/Δ5–8 and
Rgs12fl/fl) was recently described in Gross et al. [32]. To generate mice conditionally lacking
RGS12 in satellite cells, Rgs12fl/fl mice were bred with Pax7::Cre mice, purchased from The
Jackson Laboratory (Pax7tm1(cre)Mrc/J; Stock No: 010530). Both mouse strains were maintained
in the C57BL/6J background. C57BL/10ScSn-Dmdmdx mice were also purchased from The
Jackson Laboratory (Stock No: 001801). Female Dmdmdx/mdx mice were bred with male
homozygous Rgs12fl/fl; Pax7::Cre mice to generate hetero-/hemizygous male Rgs12+/fl; Pax7::
Cre; Dmdmdx/Y mice. Male Rgs12+/fl; Pax7::Cre; Dmdmdx/Y mice were crossed with female
Dmdmdx/mdx mice to generate male and female mice hemizygous and homozygous for
Dmdmdx, respectively (hereto referred to collectively as mdx mice). Male Rgs12+/fl; Pax7::Cre;
Dmdmdx/Y and female Rgs12+/fl; Pax7::Cre; Dmdmdx/mdx mice were subsequently intercrossed
to produce both mdx mice conditionally lacking RGS12 in Pax7+ satellite cells (Rgs12fl/fl;
Pax7::Cre; Dmdmdx) and control littermate mdx mice with the wild-type Rgs12 allele (Rgs12+/+;
Pax7::Cre; Dmdmdx). Mice were housed under standard temperature, humidity, and lighting
conditions (12 h light/12 h dark); all mice were provided food and water ad libitum. All experi-
ments were conducted on approved protocols in accordance with the West Virginia University
Animal Care and Use Committee and followed the National Institute of Health and AAALAC
guidelines for use of rodents in research.
CTX-induced muscle injury
Intramuscular injection of CTX was performed as previously described [33, 34]. Briefly, mice
were anesthetized via inhalation of 2% isoflurane. Mouse legs were shaved and cleaned with
alcohol. Hind limb muscle(s) were injected with 100 μl of CTX or sterile saline with a 28-gauge
needle. After injection, mice were returned to their home cage and monitored until they fully
regained consciousness. Hind limb muscle(s) were then harvested at the indicated time points
and processed as described.
Mouse skeletal muscle harvest, myoblast isolation, and myoblast culture
Skin and fascia were removed from euthanized mice and hind limb muscle(s) isolated (remov-
ing excess visible fat tissue). Muscles were either flash frozen for subsequent histological analy-
ses or RNA and protein extraction, or fresh muscles were placed into sterile tissue-culture
plasticware under phosphate-buffered saline (PBS) to pool sufficient tissue for myoblast isola-
tion. Mouse primary skeletal muscle tissue was harvested from young mice (aged 2–3 weeks),
cultured, and processed for fluorescence-activated cell sorting (FACS; ref. [35]) using previ-
ously described techniques [10, 36, 37] as modified below. Briefly, isolated muscle tissue was
removed, minced with sterile scissors under sterile conditions, and transferred to new tissue-
culture plasticware (6 cm dish) for treatment with collagenase/dispase solution (10 mg/mL
Collagenase B [Roche] and 2.5 mM CaCl2 in Dispase II solution [Roche]). Tissue was then
minced further with sterile #10 scalpel blades; tissue slurry was then processed by two rounds
of incubation at 37 oC for twelve minutes with intervening trituration to homogenize mixture,
prior to filtration using PBS through a pre-wetted 40-μm nylon-mesh cell strainer (Fisher Sci-
entific). Filtered cells were pelleted by centrifugation for 5 min at 1,000 x g, resuspended in
Ham’s Complete medium (Ham’s F-10 medium [Gibco] containing 20% fetal bovine serum
[FBS], 2.5 ng/mL basic fibroblast growth factor [bFGF; Sigma], penicillin/streptomycin, and
fungizone), triturated through a 20G-gauge needle six times, and plated for 2 hours at 37 oC
and 5% CO2 to remove fibroblast contamination, before being re-pelleted by centrifugation
and transferred to collagen-coated tissue-culture plasticware (rat tail collagen obtained from
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Roche) in fresh Ham’s Complete medium. Cultures were re-fed Ham’s Complete medium
every 2 days and passaged before reaching 80% confluency. Cultures to be tested for ex vivo
differentiation were plated at a higher density (80%) and transferred into Dulbecco’s modified
Earle’s medium (DMEM; Gibco) supplemented with 2% horse serum and penicillin/strepto-
mycin. Cultures of primary myoblasts from conditional Rgs12-knockout mice were main-
tained in Ham’s Complete medium and infected overnight with Cre- (or GFP-only)
expressing AAV prior to harvest and lysis for immunoblotting.
Immunoblotting
Cells and tissue were lysed in ice-cold RIPA buffer with protease inhibitors (Roche). Tissues
were minced in a 1.5 mL Eppendorf tube prior to homogenization using a bench top rotor sta-
tor. Cell and tissue lysates were sonicated on ice prior to being clarified by centrifugation at
20,000 X g for 15 minutes. Protein content was quantified by the Bradford protein assay using
BSA as a standard. Lysates were diluted in Laemmli buffer (BioRad, Hercules, CA) and
resolved on 4–16% pre-cast SDS-polyacyrlamide gels (BioRad), transferred to nitrocellulose
membranes, immunoblotted with primary (overnight, 4˚C) and HRP-conjugated secondary
antibodies (e.g., Sigma #A5278 at 1:1000 dilution, 1 h at room temperature), and visualized by
chemiluminescence (Pierce ECL Substrate or SuperSignal West Dura Extended Duration
Substrate).
RNA extraction and quantitative real-time polymerase chain reaction
(qRT-PCR) procedure
RNA extraction and qRT-PCR procedures were previously described by Schroer et al. [38].
Briefly, TRIzol reagent (Invitrogen) was used to extract RNA from both tissue and cells. Mus-
cle tissue was minced and homogenized using a bench top rotor stator. RNA was extracted
according to manufacturer’s instructions using the Direct-zol RNA MiniPrep kit from Zymo
Research. Reverse transcription and genomic DNA elimination was performed using the
QuantiTect Reverse Transcription Kit from Qiagen. Two microliters of cDNA were used in
each PCR reaction using the QuantiTect SYBR Green PCR Master Mix (Qiagen). Primers
(10 μM) were designed for Rgs12 mRNA (spanning exons 5–6) sequence elements (fwd
primer: 50-CATCAGCAACAACAGCCTGA-30; rev primer 50-CATGACTGAAGCAC
TCACAGG-30). Primer sequences for eMHC were described previously
[39] (fwd primer: 5’-AAAAGGCCATCACTGACGC-3’; rev primer: 5’-CA
GCTCTCTGATCCGTGTCTC-3’) and were purchased from ThermoFisher Scientific. RT2
qPCR Primer Assay kits for mouse 18S rRNA and Gapdh were purchased from Qiagen. PCR
was performed in a Qiagen Rotor Gene-Q system (initial 15 min denaturation at 95˚C fol-
lowed by 40 cycles of 15 s denaturation at 95˚C, 30 s annealing at 60˚C, and 30 s extension at
72˚C). We utilized the SYBR green dye qPCR technique to detect double-stranded PCR ampli-
cons as they accumulated during PCR cycling. Melting curves were obtained after each
qRT-PCR experiment to assure specificity of resultant amplicons. Relative quantification of
gene expression was performed using the ΔΔCt method [40] with 18s rRNA and Gapdh chosen
as stable housekeeping genes.
Immunofluorescence analyses
Cultures of adherent cells were grown on glass coverslips, fixed in PBS containing 4% parafor-
maldehyde, permeabilized in PBS containing 0.1% Triton X-100, and then stained using pri-
mary and fluor-conjugated secondary antibodies (and often with DAPI as a nuclear DNA
stain) as indicated in the Results section and Figure legends. Stained cell cultures were then
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bonded in Vectashield and imaged using epifluorescence on an IX70 Olympus microscope.
Single-color images were pseudocolored and overlaid in Photoshop (CS6, Adobe).
Lipid dot-blot protein overlay assay
Recombinant Schistosoma japonica glutathione-S-transferase (GST), and GST fusions with the
N-terminal PDZ and PTB domains of RGS12 (i.e., amino-acids 9 to 406 of UniProt O08774),
were separately expressed in E. coli and purified by high-pressure liquid chromatography
(HPLC) as per previously published protocols [41]. Each purified protein was incubated (at a
final concentration of 20 μg/mL protein within blocking buffer of 0.1% Tween-20 and 3% BSA
in phosphate-buffered saline) for 1 hour at room temperature with a lipid dot-blot membrane
(PIP Strip; cat #P-6001 from Echelon Biosciences, Salt Lake City UT) that had been pre-
blocked by overnight incubation in blocking buffer at 4 oC with gentle agitation as per manu-
facturer’s protocol. After three consecutive, ten-minute washes with blocking buffer lacking
BSA, membranes were incubated with anti-GST monoclonal antibody (Sigma #G1160; 1:2000
dilution in blocking buffer), washed again three times, incubated with anti-mouse horseradish
peroxidase (HRP) secondary antibody (Sigma #A5278; 1:2000 dilution in blocking buffer),
washed again three times, and then protein/lipid-spot interactions detected using the same
chemiluminescence protocol as used for immunoblotting described above.
Stable over-expression of oncogenic H-Ras in the myoblastic C2C12 cell
line
Cultures of the parental C2C12 myoblastic cell line were transfected with expression vector
DNA (encoding myc-tagged H-Ras(G12V); a gift from UNC colleague Dr. Channing Der)
and Lipofectamine 2000 (Invitrogen) as per manufacturer’s instructions. Transfected cells
were then selected in culture medium containing 10% FBS and 1 mg/mL hygromycin for two
weeks, prior to clonal dilution, expansion under constant drug selection, and screening of
whole cell lysates via immunoblotting with anti-Myc epitope antibody 9E10.
Co-immunoprecipitation
Protein co-immunoprecipitation experiments were conducted using previously described
techniques [37] and reagents [6, 7].
Stable RGS12 over-expression in the myoblastic C2C12 cell line
Cultures of the C2C12 cell line were separately transfected with a control yellow-fluorescent
protein (YFP) expression vector or either an HA epitope-tagged or Flag epitope-tagged, full-
length RGS12 expression construct [6, 7], using Lipofectamine 2000 (Invitrogen) as per manu-
facturer’s directions. Twenty-four hours later, cells were cultured in drug-selection medium
(GM + 1 mg/mL G418 for Flag-RGS12; GM + 1 mg/mL hygromycin for HA-RGS12) for two
weeks. Stably-selected C2C12 cell populations were switched from GM (DMEM + 10% FBS)
to DM (DMEM + 2% HS) for two days. To quantify differentiation, cell cultures were then
fixed with para-formaldehyde, permeabilized, and stained with a primary antibody to sarco-
mere myosin heavy chain MHC (DSHB cat# MF 20; Antibody Registry ID AB_2147781) and
Alexa-fluor 594 secondary antibody (Molecular Probes); nuclei were counterstained with
DAPI. Myotube formation within derived C2C12 cell line cultures was quantitated by calcula-
tion of the fusion index, as previously described [42]. Briefly, nuclei from MHC-positive,
multi-nucleated cells and MHC-negative, non-fused cells were separately counted using Ima-
geJ software and the fusion index calculated as the ratio of nuclei present in fused MHC-
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positive cells to the total number of nuclei in the field (expressed as a percentage). Mock trans-
fected and myc-RGS12-overexpressing cultures of C2C12 cells were incubated with EdU for
60 minutes, to obtain proliferation indices, and click-iT labeling and DNA counterstaining
was performed directly as per manufacturer’s protocol (Click-iT EdU Alexa Fluor 488 kit;
ThermoFisher). The percentage of Alexa fluor 488-positive cells was assessed using ImageJ
software.
Stable knockdown of RGS12 expression in the myoblastic C2C12 cell line
To create C2C12 cells with stable decreases in RGS12 protein expression, cultures of the paren-
tal C2C12 line were infected with lentiviridae encoding either a non-specific control shRNA or
one of two different shRNAs targeting Rgs12 (#2, #5) and then selected in puromycin-contain-
ing growth medium (DMEM + 10% FBS) for two weeks. Cell cultures were then switched
from growth medium to differentiation medium (DMEM + 2% HS) for five days; as a positive
control for low-to-nil fusion index, the poorly-differentiating, human RD cell line was also cul-
tured for five days in differentiation medium (rightmost panel). Quantification of C2C12 cell
line differentiation, via the fusion index, was performed as described above.
RGS12 over-expression and myotube formation assays in primary mouse
myoblasts
Cultures of primary mouse myoblasts were separately transfected with a control (empty
pcDNA3.1 vector) or HA epitope-tagged full-length RGS12 expression construct [6, 7], using
Lipofectamine 2000 (Invitrogen) as per manufacturer’s directions. Cultures of primary mouse
myoblasts at 80% confluence were switched from GM (Ham’s F-10 + 20% FBS) to DM
(DMEM + 2% HS) for 48 hours. Post-differentiation, cell cultures were fixed with para-formal-
dehyde, permeabilized, and stained with a primary antibody to sarcomere myosin heavy chain
MHC (DSHB cat# MF 20; Antibody Registry ID AB_2147781) and Alexa-fluor 594 secondary
antibody (Molecular Probes); nuclei were counterstained with DAPI. Myotube formation in
primary myoblast cultures was quantitated using fusion index: nuclei from MHC-positive,
multi-nucleated cells and MHC-negative, non-fused cells were separately counted using Ima-
geJ software and the fusion index calculated as the ratio of nuclei present in fused MHC-posi-
tive cells to the total number of nuclei in the field (expressed as a percentage) Three separate
fields were counted for each condition.
Histological analysis of skeletal muscle
Skeletal muscles were excised from mice and placed in optimum cutting temperature (OCT)
embedding compound (Sakura Finetech) prior to being flash frozen. Eight μm thick transverse
sections of muscle were sliced using a cryostat and placed on Superfrost Microscope Slides
(Fisherbrand). Tissues sections were stained with hematoxylin and eosin (H&E) and examined
under a bright-field microscope (EVOS FL Auto). To assess skeletal muscle cross-sectional
area (CSA), sections were labeled with WGA-conjugated Alexa fluor-488 (10 μg/mL). Tissue
sections were fixed in 4% paraformaldehyde for 15 min at room temperature. Sections were
incubated at room temperature for 60 minutes with WGA-conjugated Alexa fluor-488. Sec-
tions were subsequently permeabilized with 0.3% Triton X-100 and slides were cover-slipped
with Vectashield Hardset Mounting Media containing DAPI. Sections were examined with a
fluorescent microscope (EVOS FL Auto) and scanning images of the sections were recorded.
The CSA of each myofiber was measured using the free-hand tracing tool within the EVOS FL
Auto software. At least 800 myofibers were analyzed per mouse.
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In vivo isometric force measurements
Plantar flexor muscle function was assessed as described previously [43]. Briefly, mice were
anesthetized by inhalation of a mixture of 97% oxygen and 3% isoflurane gas and placed
supine on a plate heated to 37˚C to maintain body temperature. The hindlimb was then immo-
bilized with the ankle positioned at 90˚ flexion and secured to the footplate of the dynamome-
ter (model 6350�358; Cambridge Technology, Aurora Scientific, Aurora, ON, Canada).
Subcutaneous platinum electrodes were placed on either side of the tibial nerve to activate
plantar flexor muscles. Maximal force was measured by seven sequential electrical impulses
(single pulse, 10, 20, 50, 75, 100, and 120 Hz) with five min of rest between each contraction.
Contractile data were analyzed off-line (Dynamic Muscle Analysis software; Aurora Scientific).
The maximum tension generated by the CTX injured leg was normalized to the sham PBS
injected leg of the same animal and recorded as percent recovery (i.e., (CTX tension / PBS ten-
sion) �100%). The tension generated by mdx mice was normalized to body mass to account for
differences in mouse strains.
Results and discussion
Expression of Rgs12 in mouse skeletal muscle, satellite cells, injured
muscle, and muscle-derived cell lines
Confirming our prior findings of skeletal muscle expression of RGS12 beginning at embryonic
day 9.5 during mouse development [10], more recent data [44] from whole transcriptome
shotgun sequencing (RNA-Seq) of mouse gastrocnemius muscle-derived RNA from various
developmental stages indicate that Rgs12 is expressed in developing skeletal muscle during
fetal and early postnatal time points, and this expression fades over time in mature adult skele-
tal muscle (Fig 1A; Gene Expression Omnibus GSE108402). In microarray-based expression
studies, Rgs12 is also observed to be expressed in Pax7-positive satellite cells from embryonic
day E17.5 mice [45]; while still detectable in adult mice, Rgs12 expression decreases over time
in the Pax7-positive satellite cell population (Fig 1B), coinciding with the typical timing of sat-
ellite cells moving to a quiescent state [46]. In contrast, Rgs14, the closest paralog to Rgs12 and
itself a MAPK scaffold [37, 47], is expressed at a lower level than Rgs12; furthermore, Rgs14
expression levels are relatively unaltered by age (Fig 1A and 1B).
In addition to being elevated during embryonic myogenesis, Rgs12 expression was also
increased during adult myogenesis. Specifically, Rgs12 transcript is seen transiently upregu-
lated in TA muscle undergoing repair: i.e., four-fold increased two days following CTX-
induced injury, then returning to levels equivalent to uninjured muscle four days after CTX
injection (Fig 1C). In contrast, the embryonic form of myosin heavy chain (eMHC), a differen-
tiation marker of regenerating myofibers [34, 48], was not observed to be upregulated until
four days after CTX-induced injury, and remained elevated 12 days after CTX injection, indi-
cating that Rgs12 levels are downregulated upon the differentiation and maturation of regener-
ating myofibers.
To investigate whether observed decreases in Rgs12 expression over time are directly associ-
ated with the transition from myoblast proliferation to differentiation, we examined Rgs12
mRNA and RGS12 protein levels in the C2C12 myoblastic cell line, a commonly used in vitro
model [49] that can be maintained in a proliferative state by culture in 10% fetal bovine serum,
or rapidly switched toward differentiation into myotubes upon culturing them instead in 2%
horse serum. By 24 hours after the switch to differentiation medium, Rgs12 transcript levels
were observed to drop to 50% compared with proliferating C2C12 cells (Fig 1D); by 72 hours
after the switch to differentiation medium, RGS12 protein expression was barely detectable by
RGS12 in myogenesis
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immunoblotting (Fig 1D). These findings suggest that RGS12 expression declines during myo-
blast differentiation.
RGS12 is associated with activated H-Ras and early (but not late)
endosomes in C2C12 cells
RGS12 protein was seen by immunoblotting to be expressed within a human rhabdomyosar-
coma RD cell line, proliferating C2C12 cells, and isolated primary myoblasts from mouse gas-
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Fig 1. Rgs12 expression is high in mouse embryonic skeletal muscle and active satellite cells, upregulated early during muscle repair, and downregulated upon
differentiation of the myoblastic C2C12 cell line. (A) Relative expression (mean ± SEM of Fragments Per Kilobase of transcript per Million mapped reads [FPKM]) of
Rgs12, Rgs14, and Pax7 gene transcripts within indicated ages of mouse gastrocnemius muscle samples was obtained via RNA-Seq using an Illumina HiSeq 2000. Based
on Gene Expression Omnibus dataset GSE108402 [50]. Inset, detection of RGS12 protein expression via immunoblotting of (a) 100 μg of whole gastrocnemius muscle
lysate from a 3-month-old C57BL/6J mouse and (b) 50 μg of lysate from myoblasts isolated from cardiotoxin-injected tibialis anterior (TA) muscle. (B) Normalized
expression levels (mean ± SEM) of Rgs12, Rgs14, and Pax7 gene transcripts within indicated ages of flow-sorted, Pax7+ mouse skeletal muscle satellite cells were
obtained via an Affymetrix Mouse Gene 1.0 ST microarray, based on Gene Expression Omnibus dataset GSE47401; published in [51]. (C) Relative expression of Rgs12
and eMHC in TA muscle following CTX-induced muscle damage. RNA was extracted from muscle at the indicated time points and quantified using qRT-PCR, with
Gapdh abundance as an internal control. �, p< 0.01 Rgs12 level compared to time zero (one-way ANOVA with Dunnett’s test); #, p< 0.0001 eMHC level compared to
time zero (one-way ANOVA with Dunnett’s test). Inset, TA muscle was injected with 0.1 ml of 10 μM cardiotoxin (CTX) diluted in PBS; contralateral, PBS-injected TA
muscle was used as a control. After four days, the muscles were harvested and used for RGS12 protein expression analysis by immunoblotting (with GAPDH protein
levels interrogated in parallel as a loading control). (D) C2C12 cell line cultures (4 x 105 cells/well) were maintained in growth medium (DMEM containing 10% fetal
bovine serum [FBS]) for two days. Differentiation was induced by replacing growth medium with differentiation medium (DMEM containing 2% horse serum [HS]
instead of FBS). Total RNA and protein lysates were separately isolated from cell cultures at the indicated time points (hours) after the switch to differentiation medium.
Rgs12 mRNA and RGS12 protein levels were determined by qRT-PCR and immunoblotting, respectively. GAPDH mRNA and protein levels were used as internal
controls for each experiment. ��, p< 0.01; ���, p< 0.001 versus level observed at time zero (one-way ANOVA with Dunnett’s test).
https://doi.org/10.1371/journal.pone.0216167.g001
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localization within cytosolic puncta of proliferating C2C12 cells; by contrast, the poorly differ-
entiating human rhabdomyosarcoma RD cell line [52] was observed to express RGS12 pre-
dominantly in the nucleus (Fig 2B). A nuclear localization for RGS12 in RD cells likely reflects
its reported function as a transcriptional repressor that affects MNX1 expression and AKT
activity [9, 53]; this function is presumably in contrast to (or at least independent of) its estab-
lished role as an endosomally targeted, G protein/MAPK signalsome scaffold when localized






































































Fig 2. RGS12 expression is observed in cytosolic puncta within the myoblastic C2C12 cell line, but localized in the nucleus in the poorly
differentiating human RD cell line. (A) Immunoblotting (IB) of cell lysates from all three cell types indicates RGS12 protein expression, as detected
using a rabbit anti-RGS12 polyclonal antibody previously described [7]; β-tubulin protein levels were also examined by immunoblotting in parallel as a
loading control. (B) Cultures of the poorly differentiating, human rhabdomysarcoma RD cell line and the more-easily differentiated, mouse C2C12 cell
line were separately fixed and stained with DAPI; RGS12 protein was detected by indirect immunofluorescence using UNC60-26.2.1. Panels (i-vi)
represent: (i, iv) anti-RGS12 antibody detection with Alexa-fluor-594 secondary antibody; (ii, v) DAPI nuclear stain; and, (iii, vi) overlay of both images.
(C) Endogenous RGS12 localizes to early (APPL1-positive) endosomes within C2C12 cells. C2C12 cell line cultures (4 x 105 cells/well) were maintained
in growth medium (DMEM containing 10% fetal bovine serum [FBS]) for two days. Cells were then fixed in paraformaldehyde, permeabilized, and
stained with primary mouse monoclonal antibody UNC60-26.2.1 and secondary Alexa-fluor-594 anti-mouse antibody, alone or in combination with
primary anti-APPL1 or -Rab9 rabbit polyclonal antibodies followed by Alexa-fluor-488 secondary anti-rabbit antibody. Overlays in panels (vii-ix) are
absent the DAPI nuclear stain (blue) to highlight lack of overlap between RGS12 and Rab9 signals. (D) RGS12 N-terminus binds to select
phosphatidylinositides in a lipid dot-blot protein overlay assay. A “PIP Strip” nitrocellulose membrane pre-spotted with the indicated phospholipid
species was probed with 20 μg/mL of GST alone, recombinant GST-RGS12 protein (amino-acids 9–406 spanning PDZ and PTB domains; “WT”), or
GST-RGS12(aa 9–406) protein with alanine substitutions to four arginines in the PTB domain (Arg-255, -260, -262, and -308; “4R!A”) previously
predicted by electrostatic contouring [61] to be involved in phospholipid binding. After extensive washing, the binding of protein to phospholipid spots
was detected by chemiluminescence using anti-GST mouse monoclonal antibody and anti-mouse-horseradish peroxidase conjugated secondary
antibody. Lipid abbreviations: LPA, lysophosphatidic acid; LPC, lysophosphocholine; PI, phosphatidylinositol; PE, phosphatidylethanolamine; PC,
phosphatidylcholine; S1P, sphingosine-1-phosphate; PA, phosphatidic acid; PS, phosphatidylserine.
https://doi.org/10.1371/journal.pone.0216167.g002
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Given the punctate nature of the RGS12 expression pattern observed in C2C12 cells, we
performed dual-label immunofluorescence staining to assess whether RGS12 was potentially
associating with early or late endosomes. As shown in Fig 2C, RGS12 expression was coinci-
dent with that of the early endosomal marker APPL1 [56], but not that of the late endosomal
marker Rab9 [57], in C2C12 cells. This association profile is consistent with our prior observa-
tions of RGS12 association with the early endosomal marker EEA1 within PC12 cells treated
with nerve growth factor (NGF) to induce neuritogenesis [7]. In addition, APPL1-containing
early endosomes have been reported to serve as platforms for MAPK signalsome assembly
[58], reinforcing the notion that RGS12 may serve as a MAPK scaffold in myoblasts similar to
its function in developing neurons [7]. Endosomal targeting of RGS12 is also consistent with
our in vitro finding (Fig 2D) that the N-terminal PTB domain of RGS12 interacts with phos-
phatidylinositol lipids including PtdIns(3)P and PtdIns(5)P, two lipid species known to have
roles in intracellular membrane compartments and endosomal trafficking [59, 60]
Metastatic rhabdomyosarcoma is a skeletal muscle satellite cell-derived cancer [62] in
which oncogenic H-Ras mutations and increased ERK activity have been described [63–65].
As we have previously shown that RGS12 can assemble an activated H-Ras-driven MAPK sig-
nalsome within dorsal root ganglion neurons [7], observations of differential RGS12 localiza-
tions within cultures of poorly differentiable RD cells vs easily differentiable C2C12 cells (Fig
2) prompted us to investigate the relationship between RGS12 and H-Ras in the latter (Fig 3).
H-Ras activation (upstream of ERK1/2 activation) promotes proliferation and inhibits myo-
tube formation, an early myogenic step, whereas inactivation of ERK1/2 is necessary for myo-
genesis to occur [66, 67]. Clones of the C2C12 cell line stably expressing activated H-Ras were
therefore established; clone 9, with the highest stable expression of activated H-Ras (e.g., Fig
3A), was chosen for further characterization, especially given evidence of endogenous RGS12
interaction with the ectopically expressed, oncogenic H-Ras mutant in this stable sub-line
(Fig 3B).
Oncogenic H-Ras expression affects C2C12 differentiation and RGS12
stability
Stable overexpression of oncogenic H-Ras in C2C12 cells has previously been shown to inhibit
myotube formation under in vitro culture conditions that normally drive myoblast differentia-
tion [24–26]. An established means to assess such myoblast differentiation in vitro is measure-
ment of the fusion index [68, 69], which quantifies the presence of sarcomere myosin heavy
chain (MHC)-expressing, multi-nucleated myotubes as enumerated by immunofluorescence
detection via the MF20 anti-MHC antibody and DAPI nuclear staining, respectively. After 5
days of culture in low serum (differentiation medium), the parental C2C12 line formed MHC-
positive myotubes (Fig 3C, panel ii). In contrast, the daughter line expressing oncogenic
H-Ras did not form myotubes (Fig 3C, panel iv) and, thus, no fusion index could be
calculated.
The oncogenic H-Ras mutant was observed to co-immunoprecipitate with ectopically over-
expressed RGS12 in the C2C12 cell line (Fig 3D); in addition, co-expression of RGS12 with
oncogenic H-Ras appears to increase the amount of RGS12 expressed upon its transient co-
transfection (compare lanes 2 and 4 of Fig 3D). In contrast to the loss of RGS12 levels seen in
the parental C2C12 cell line after culturing in differentiation medium (Fig 3E), the C2HRas#9
cell line showed no loss of RGS12 expression when switched to differentiation medium (albeit
with constant drug (hygromycin)-selection pressure). A proteasome-dependent path to
RGS12 protein degradation during myoblast differentiation may be operative in C2C12 cells,
as this would be consistent with findings reported for the Drosophila RGS12 ortholog, Loco,
RGS12 in myogenesis
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Fig 3. RGS12 interacts with activated H-Ras and is downregulated within the C2C12 cell line during differentiation. (A) Immunoblotting (IB) of cell lysates from
three stable clones of the C2C12 cell line indicating their stable expression of a constitutively-active, GTPase-deficient (G12V) mutant of H-Ras protein (via detection of
its N-terminal myc-epitope tag). (B) Co-immunoprecipitation of myc-tagged, activated H-Ras (G12V mutant) with endogenous RGS12 protein expressed in the
C2HRas cell line clone 9. IP: immunoprecipitation; IB: immunoblotting. (C) To test the effect of stable expression of activated H-Ras on myoblast differentiation in
vitro, multi-nucleated myotube content of indicated cell populations (either parental C2C12 cells [panels i, ii] or C2HRas clone #9 cells [panels iii, iv]) was measured by
fixation and staining for sarcomere myosin (MHC; green) and nuclear DNA content (DAPI; pseudocolored red), either pre-differentiation (panels i, iii) or post-
differentiation by culture for 5 days in low serum (2% horse serum; panels ii, iv). The mean fusion index for several C2C12 cell populations was 40% (± 2.5%; SEM),
consistent with other reports [68, 69]. In contrast, the C2HRas cell line clone 9 was incapable of myotube formation (panel iv) and no fusion index could be calculated.
(D) Co-immunoprecipitation of myc-tagged, activated H-Ras (G12V mutant) with ectopically co-expressed, HA-tagged RGS12 in C2C12 cells. IgH: immunoglobulin
heavy-chain. (E) Endogenous levels of RGS12 protein are down-regulated during C2C12 differentiation into myotubes (i.e., 7 days of culture in low serum medium),
whereas the same culture conditions did not lower RGS12 levels within the C2HRas cell line clone #9. (F) Mammalian RGS12 proteins encode a “destruction box”
recognition motif, conforming to the consensus RxxLxxxx(D/N), where “x” is any amino-acid, that is found in most substrates of the Anaphase-Promoting Complex
(APC). This destruction box sequence is completely conserved across human (h), mouse (m), and rat (r) RGS12 proteins (i.e., amino acids 402–410 of mouse RGS12:
RAFLDGDAD); this consensus motif is preserved in zebrafish (z) and Drosophila (d) RGS12 orthologs, as well as in the APC targets Skp2 and Myf5.
https://doi.org/10.1371/journal.pone.0216167.g003
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which is ubiquitinated and degraded in an Anaphase-Promoting Complex (APC)- and
Cdh1-dependent process during glial differentiation in the developing fruit fly [70]. Mamma-
lian RGS12 proteins share a destruction box motif [71] with Skp2 and Myf5 (Fig 3F); Cdh1, a
regulatory component of APC, targets Skp2 and Myf5 for degradation, resulting in cell cycle
withdrawal and myogenic fusion [72]. Thus, RGS12, like Loco, may be a target of Cdh1 for
ubiquitin-mediated degradation during myoblast differentiation.
Altered expression of RGS12 affects the balance between C2C12 cell
proliferation and differentiation
Given these data suggesting a potential role for regulated RGS12 levels in affecting myoblast
cell fate, we examined the effect of ectopic RGS12 over-expression on C2C12 myotube forma-
tion. A pronounced increase in myotube formation was observed even after just 2 days of cul-
ture in low serum differentiation medium, upon transient overexpression of either HA- or
Flag-tagged, full-length RGS12 protein (Fig 4A–4C). Proliferation, as assessed by EdU incor-
poration, decreased commensurately following RGS12 ectopic over-expression (Fig 4D
and 4E).
We next examined the consequences of reducing RGS12 expression in the C2C12 cell line,
using lentiviral-mediated transduction of short hairpin RNAs (shRNAs) targeting the Rgs12
transcript (Fig 4F–4I). Two independent shRNAs, separately targeting either the open-reading
frame or 3’ untranslated region of the Rgs12 transcript, each greatly reduced expression of the
~160 kDa full-length RGS12 protein (Fig 4H) and also greatly reduced the production of myo-
tubes after 5 days of culture in low serum differentiation medium (fusion index quantified in
Fig 4I); as expected, culturing the human rhabdomyosarcoma RD cell line for five days in dif-
ferentiation medium was not observed to induce myotube formation in vitro (Fig 4F and 4G,
rightmost panels). Phospho-ERK1/2 content was significantly reduced in later days during
the five-day treatment with differentiation medium (e.g., days 4 and 5 for non-transfected
C2C12 cells; Fig 4G); this reduction was not evident in RD cells under the same five-day treat-
ment, nor in C2C12 cell lines with effective shRNA-mediated RGS12 knockdown (#2 and #5;
Fig 4F–4I).
Ablation and re-expression of RGS12 both affect the differentiation of
explanted mouse primary myoblasts
We recently produced a mouse strain constitutively deficient in RGS12 expression and used it
to investigate the role of RGS12 in primary myoblast cell fate. This mouse strain is a conven-
tional (i.e., constitutive) knockout of Rgs12 exons 5–8 and, as previously reported [32], mice
homozygous for the Rgs12 knockout (Rgs12Δ5-8/Δ5–8) are grossly normal, fertile, and show
Mendelian inheritance; an initial survey conducted by UNC’s Behavioral Phenotyping Core
(Dr. Sheryl Moy, director) revealed no overt deficits in motor, reflexive, or sensory abilities.
Consistent with results from RGS12-directed RNAi in C2C12 cells (Fig 4F–4I), primary myo-
blasts isolated from Rgs12Δ5-8/Δ5–8 mice (Fig 5A) exhibit significantly reduced myoblast-to-
myotube differentiation after 48 hours of ex vivo culture in reduced serum-containing medium
(Fig 5B). After two days in differentiation medium, Rgs12Δ5-8/Δ5–8 primary myoblast cultures
exhibit an approximately 50% reduction in myogenin induction, as compared with wild-type
(Rgs12++/+/+) primary myoblast cultures treated in the same fashion (Fig 5C); however, Pax7
and Myf5 reduction, and MRF4 induction, were unchanged. Rgs12Δ5-8/Δ5–8 myoblasts trans-
fected with an RGS12 expression vector and subsequently cultured in reduced serum-contain-
ing medium exhibited levels of fusion indistinguishable from those of wild-type myoblasts
(Fig 5D).
RGS12 in myogenesis
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Tissue-restricted RGS12 loss leads to normal skeletal muscle development
but delays repair
We recently generated a second mouse strain to complement the constitutive Rgs12Δ5-8/Δ5–8
mouse: specifically, a mouse strain harboring a floxed allele of the Rgs12 gene that allows for
Cre recombinase-mediated excision of the RGS domain-encoding exons 5 and 6 that are
flanked by loxP sites [32]. This second strain allows for tissue-specific, conditional knockout of
RGS12 function. Preparations of primary myoblasts from Rgs12fl/fl P9 neonates were infected
with GFP-tagged Cre recombinase- or GFP-transducing (negative control) adeno-associated
viruses (obtained from the U. Penn. Virology Core Facility) and subsequently analyzed for
RGS12 expression by immunoblot analysis. Viral transduction of Cre recombinase, but not of
GFP alone, resulted in undetectable levels of RGS12 protein expression (Fig 6A).
To help identify an in vivo role for RGS12 specifically within skeletal muscle satellite cells,
we cross-bred our Rgs12fl/fl mice with a Pax7::Cre driver strain (Pax7 tm1(cre)Mrc /J). This latter
strain [73] retains normal Pax7 function while expressing Cre recombinase under the control
of the Pax7 promoter in skeletal muscle satellite cells [74–76]. Using two, independent, mono-
clonal RGS12 antibodies (Fig 6Bi), we confirmed the presence of RGS12 protein in the TA
muscle of wild-type mice, but RGS12 was absent in Rgs12fl/fl; Pax7::Cre mice. As an additional
control for the specificity of these antibodies, we confirmed RGS12 protein in the cortex of
wild-type mouse brain (Fig 6Bi), as previously reported [32].
Mice lacking RGS12 in Pax7+ satellite cells were observed to be grossly normal and, when
bred from heterozygous crosses (i.e., Rgs12fl/+; Pax7::Cre × Rgs12fl/+; Pax7::Cre), were born in
a normal Mendelian ratio of 1:2:1. Rgs12 expression in satellite cells did not appear to be neces-
sary for myogenesis during development under normal conditions, as skeletal muscle from
Fig 4. Ectopic RGS12 over- and under-expression affects myotube formation by the C2C12 cell line. (A)
RGS12-overexpressing and control C2C12 cell line cultures were each switched from growth medium (DMEM, 10%
FBS) to differentiation medium (DMEM, 2% horse serum) and cultured for two days. Cells were then fixed with
paraformaldehyde and stained with anti-MHC antibody (MF20) and Alexa-fluor-594 secondary antibody (red). Nuclei
were visualized with DAPI staining (blue). (B) Differentiation to myotubes was quantitated by the fusion index [36,
42): namely, the percentage of nuclei present in fused, MHC-positive cells vs total nuclei in the field. Graphed below
the fusion index is the quantitation of MHC-positive cells observed in each field examined. Statistical significance was
tested by one-way ANOVA: ��, p<0.01; ���, p<0.001. (C) Expression of epitope-tagged, full-length RGS12 was
confirmed by immunoblotting (IB) with indicated anti-epitope tag antibodies. (D) Ectopic expression of Myc-epitope
tagged, full-length RGS12 was verified by immunoblotting (IB) of whole cell lysates; equal total protein loading was
verified by β-tubulin detection. (E) RGS12-overexpressing and mock transfected (empty vector) C2C12 cell line
cultures in growth medium (DMEM, 10% FBS) were separately incubated for 60 minutes with 5-ethynyl-2’-
deoxyuridine (EdU) to detect DNA synthesis by proliferating cells. Click-iT labeling with Alexa-fluor-488 identified
cells with newly synthesized DNA. The percentage of EdU positive cells were counted using ImageJ software. N = 3
independent experiments. Statistical significance was established by Student’s t-test: ���, p<0.001. (F) C2C12 cell
cultures were infected with lentiviridae encoding either a non-specific (NS) control shRNA or one of two different
shRNAs targeting Rgs12 (#2, #5), and then selected in puromycin-containing growth medium (DMEM + 10% FBS) for
two weeks. Cell cultures were then switched from growth medium to differentiation medium (DMEM + 2% HS) for
five days; as a positive control for low-to-nil fusion index, the poorly-differentiating, human RD cell line was also
cultured for five days in differentiation medium (rightmost panel). Cell cultures were immunolabeled with a primary
antibody directed against sarcomere MHC (MF20) and Alexa-fluor-594 secondary antibody; nuclei were
counterstained with DAPI. (G) Underneath each fluorescence micrograph is the plot of phospho-ERK content
(quantified by densitometry and normalized to total ERK content) from parallel cultures harvested at indicated
timepoints; immunoblot inset within graph presents representative data from nontransfected RD cells over five days of
culture. (H) shRNA-mediated knockdown of RGS12 expression was confirmed by immunoblotting of whole cell
lysates from indicated, shRNA-expressing C2C12 cell lines; β-actin protein levels were also examined by
immunoblotting in parallel as a loading control. (I) Myotube formation within indicated C2C12 cell cultures was
quantitated by calculation of the fusion index: nuclei from sarcomere MHC-positive, multi-nucleated cells and MHC-
negative, non-fused cells were separately counted using ImageJ software and the fusion index calculated as the ratio of
nuclei present in fused MHC-positive cells to the total number of nuclei in the field (expressed as a percentage). ���,
p< 0.005 versus control shRNA-expressing C2C12 cell line; Student’s t-test.
https://doi.org/10.1371/journal.pone.0216167.g004
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Fig 5. Myotube formation by primary myoblasts isolated from RGS12-null mice is disrupted, but restored upon RGS12 re-
expression. (A) Confirmation of RGS12 loss in primary myoblasts from Rgs12Δ5-8/Δ5–8 mice via immunoblotting of myoblast
lysates with indicated antibodies. Skeletal muscle myoblasts were isolated from tibialis anterior (TA) muscles of 2- to 3-week old
homozygous Rgs12Δ5-8/Δ5–8 mice, heterozygous Rgs12+/Δ5–8 mice, or wild-type littermate controls, and cultured in F10 Ham’s
medium with 20% FBS and 2.5 ng/mL bFGF prior to lysis. (B) Cultures of wild-type myoblasts or Rgs12Δ5-8/Δ5–8 myoblasts were
each switched to differentiation medium (DMEM, 2% horse serum) when at 80% confluence and cultured for an additional 2 days.
Cell cultures were then fixed, permeabilized, and stained with anti-MHC (MF20; red). Nuclei were visualized with DAPI (blue). (C)
Myoblast cultures identical to those of panel B were cultured in differentiation medium for 2 days and lysed (“post” = post-
differentiation over 2 days); parallel cultures were treated as in panel A before lysis (“pre” = pre-differentiation). Resultant lysates
were immunoblotted with antibodies against indicated proteins (β-actin as a loading control). Below the representative
immunoblots is a bar-graph of quantitated protein levels normalized as percentage change in expression between pre- and post-
differentiation samples (�, p< 0.05; Student’s t-test). (D) Separate Rgs12Δ5-8/Δ5–8 myoblast cultures were transiently transfected
using liposomes with an expression plasmid encoding full-length, HA-tagged RGS12 prior to being switched into differentiation
medium (DMEM, 2% horse serum) when at 80% confluence and cultured for an additional 2 days. Cell cultures were then fixed,
permeabilized, and stained with anti-MHC (MF20; red). Nuclei were visualized with DAPI (blue). Inset: Ectopic expression of
HA-RGS12 in Rgs12Δ5-8/Δ5–8 myoblasts was confirmed by immunoblotting with anti-RGS12 antibody. (E) Differentiation of
myoblasts to myotubes ex vivo, from micrographs as depicted in panels B and D, was quantitated by the fusion index; statistical
significance was tested by one-way ANOVA: ���, p<0.0001, RGS12-null myoblasts exhibited a significantly lower fusion index
compared to wild-type, Rgs12+/+ myoblasts; ###, p<0.0001, Rgs12Δ5-8/Δ5–8 myoblasts expressing HA-RGS12 showed statistically
significant recovery of fusion index as compared to mock-transfected Rgs12Δ5-8/Δ5–8 myoblasts. (There was no statistically
significant difference between the fusion index of wild-type myoblasts and Rgs12Δ5-8/Δ5–8 myoblasts re-expressing RGS12).
https://doi.org/10.1371/journal.pone.0216167.g005
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Rgs12fl/fl; Pax7::Cre mice appear identical to wild-type muscles in their spectrum of fiber cross-
sectional area (CSA) (Fig 6Bii, iii and 6C). Additionally, RGS12 deficiency did not impair in
vivo isometric plantar flexor force generation under normal conditions relative to wild-type
mice (Fig 6D). This observation of normal skeletal muscle development in Rgs12fl/fl; Pax7::Cre
mice is consistent with the lack of overt body-plan and motoric deficits within the conven-
tional Rgs12Δ5-8/Δ5–8 knockout mice as mentioned above.
Within Rgs12fl/fl; Pax7::Cre muscles, injected with the skeletal muscle-damaging agent CTX
and allowed to repair for eight days, there was a marked reduction in the CSA of centrally
nucleated regenerating myofibers compared with CTX-injected wild-type muscles (Fig 7A–
7C), consistent with the idea that a defect in skeletal muscle repair is engendered by RGS12
loss. Additionally, functional muscle recovery was perturbed in RGS12-deficient mice 14 days
following CTX injection. In vivo plantar flexor force generation was impaired following CTX-
induced injury (relative to the contralateral uninjured leg) in both wild-type and Rgs12fl/fl;
Pax7::Cre mice, but function trended towards being more impaired in RGS12-deficient mice
(Fig 7F). However, it appears that skeletal muscle repair is only delayed in Rgs12fl/fl; Pax7::Cre
mice. By 24 days following CTX injection, the CSA of centrally nucleated myofibers were
equivalent to those of wild-type mice (Fig 7D and 7E). Additionally, 28 days after injury plan-
tar flexor function was equivalently recovered in wild-type and Rgs12-deficient mice (Fig 7F).
Tissue-restricted loss of RGS12 does not alter the dystrophic phenotype of
mdx mice
In addition to assessing the expression of Rgs12 in response to pharmacological muscle dam-
age, we also examined expression of Rgs12 in dystrophic muscles of mdx mice (Fig 8). Rgs12
expression was found to be elevated in the quadriceps and diaphragm muscles of 12-week-old
mdx mice relative to wild-type controls (Fig 8B). To determine whether RGS12 influences the
progression of the dystrophic phenotype, we generated mdx mice conditionally lacking RGS12
in Pax7+ satellite cells (i.e., Rgs12fl/fl; Pax7::Cre; Dmdmdx mice). We examined the morphology
of quadriceps muscles from both Rgs12fl/fl; Pax7::Cre; Dmdmdx and Rgs12+/+; Pax7::Cre;
Dmdmdx mice at 24 weeks of age. Lack of RGS12 in satellite cells did not overtly alter the dys-
trophic phenotype in mdx mice (e.g., Fig 8A). To determine whether RGS12 deficiency alters
the functional deficits normally witnessed within the mdx mouse model, we examined isomet-
ric plantar flexor force generation at six, 12, and 24 weeks of age. A clear deficit was found in
the normalized maximum force generated by mdx mice at each age assessed; however, RGS12
deficiency did not alter this deficit (Fig 8C). These data suggest that loss of RGS12 may be com-
pensated for within model syndromes of prolonged bouts of muscle damage and repair. Future
Fig 6. Conditional RGS12 deficiency leads to normal skeletal muscle development. (A) Confirmation of Cre-dependent loss of the Rgs12 gene
using a conditional knockout (‘floxed allele’) strategy. Rgs12fl/fl mouse-derived primary myoblasts were cultured in vitro and infected with adeno-
associated virus (AAV) expressing green fluorescent protein (GFP only) or Cre recombinase (GFP+Cre). Evidence of Cre recombinase-mediated
excision of the Rgs12 gene (and hence loss of RGS12 expression) was obtained by immunoblotting whole cell lysate from AAV-infected myoblast
cultures with indicated anti-RGS12 monoclonal antibodies (each generated by the Siderovski lab and deposited in the Developmental Studies
Hybridoma Bank [Iowa City, IA]). (B) (i) Western blot confirmation of RGS12 expression in the tibialis anterior (TA) muscle of wild-type mice,
Pax7::Cre-dependent loss of RGS12 in the TA of Rgs12fl/fl mice, and expression of RGS12 in the cortex (brain) of wild-type mice using two
independent monoclonal RGS12 antibodies. (ii, iii) Representative scanning micrographs of TA muscles from wild-type and Rgs12fl/fl; Pax7::Cre
mice labeled with wheat-germ agglutinin (WGA; green) and nuclear DNA (blue). (C) Relative frequency distribution of the cross-sectional area
(CSA) of muscle fibers as measured by EVOS FL Auto software based on WGA staining (>800 fibers/mouse). No differences in fiber CSA were
found between genotypes. Inset: The mean CSA of muscle fibers was not different in Rgs12fl/fl; Pax7::Cre mice (n = 5) and wild-type Pax7::Cre
mice (n = 5) as assessed by a Student’s t-test (ns, not significant; p> 0.05). Data are presented as mean ± SEM. (D) Tension-frequency display of
electrically stimulated isometric plantar flexor contractions at the indicated frequencies. Mean ± SEM tension are displayed of Rgs12fl/fl; Pax7::Cre
and wild-type littermate control mice (n = 5/group). A 2-way ANOVA indicated no difference in the tension of wild-type and Rgs12-deficient
mice at the indicated frequencies.
https://doi.org/10.1371/journal.pone.0216167.g006
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experiments adding frank CTX-induced injury to muscle within Rgs12fl/fl; Pax7::Cre; Dmdmdx
mice would be worthwhile to perform to test the extent of such compensation.
Fig 7. Loss of RGS12 leads to a transient impairment in muscle repair. A, Representative cross-sections of tibialis anterior (TA) muscle from indicated mice,
labeled 8 days after cardiotoxin (CTX) injection with wheat-germ agglutinin (WGA; green) and nuclear DNA (blue). B, Representative micrographs of H&E-
stained TA muscle 8 days after CTX-induced injury. C, Relative frequency distribution of the cross-sectional area (CSA) of regenerating (i.e., centrally-
nucleated) muscle fibers 8 days after CTX injection as measured by EVOS FL Auto software based on WGA staining (>800 fibers/mouse). Differences between
Rgs12fl/fl; Pax7::Cre mice (n = 5) and wild-type Pax7::Cre mice (n = 6) were evaluated using a two-way ANOVA with Sidak’s post hoc test. ����, p<0.0001; �,
p<0.05. Inset: The mean CSA of centrally nucleated fibers was shifted towards smaller area in Rgs12fl/fl; Pax7::Cre mice vs wild-type Pax7::Cre mice as assessed
by a Student’s t-test; �, p<0.05. Data are presented as mean ± SEM. D, Representative cross-sections of TA muscle from indicated mice, labeled 24 days after
CTX injection with WGA (green) and nuclear DNA (blue). E, CSA of regenerated myofibers in TA muscle of Rgs12fl/fl; Pax7::Cre mice (n = 5) and wild-type
Pax7::Cre mice (n = 5) 24 days after CTX injury were measured by EVOS FL Auto software based on WGA staining. No differences in fiber CSA were found
between genotypes. Inset: The mean CSA of centrally nucleated fibers was not different in Rgs12fl/fl; Pax7::Cre mice (n = 5) and wild-type Pax7::Cre mice
(n = 5) as assessed by a Student’s t-test. Data are presented as mean ± SEM. F. The maximal tetanic isometric plantar flexor tension of Rgs12fl/fl; Pax7::Cre mice
(n = 5) and wild-type Pax7::Cre mice (n = 5) was obtained in both CTX and PBS treated legs at 14 and 28 days following injection. 14 days post-injection
Rgs12fl/fl; Pax7::Cre mice trended towards more impairment in the CTX injected leg relative to wild-type mice, as evaluated by a Student’s t-test (p = 0.06). By
28 days post-CTX injection, both genotypes had recovered to an equivalent level relative to their PBS-injected leg. Data are presented as mean ± SEM.
https://doi.org/10.1371/journal.pone.0216167.g007
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Conclusions
The results presented herein, from both cell culture and mouse model studies, illuminate a pre-
viously underappreciated role of RGS12 in muscle precursor-cell function. Our original report
Fig 8. Rgs12 mRNA is upregulated in skeletal muscles of Dmdmdx mice, but RGS12 loss does not appear to alter the muscle wasting phenotype of
the Dmdmdx mouse model. A, Representative micrographs of quadriceps femoris muscle from indicated mice, labeled with wheat-germ agglutinin
(WGA; green) and nuclear DNA (blue). Loss of RGS12 in satellite cells does not alter skeletal muscle morphology of mdx mice. B, Rgs12 expression was
elevated in the diaphragm (�, p<0.05) and quadriceps femoris (���, p<0.001) muscles of mdx mice as assessed by qRT-PCR analysis. Bar graph displays
the mean ± SEM; differences between wild-type and mdx mice were shown to be statistically significant by Student’s t-test. C, The maximal tetanic
isometric plantar flexor tension normalized to body weight of Rgs12fl/fl; Pax7::Cre mice (n = 5), wild-type Pax7::Cre mice (n = 5), Rgs12fl/fl; Pax7::Cre;
mdx mice (n = 5), and wild-type Pax7::Cre; mdx mice (n = 5) obtained at 6, 12, and 24 weeks of age are displayed as mean ± SEM. A two-way ANOVA
indicated mdx mice had impaired muscle function relative to Dmd wild-type mice at each age; however, Rgs12 deficiency did not alter muscle function
in mdx or Dmd wild-type mice.
https://doi.org/10.1371/journal.pone.0216167.g008
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[10], that RGS12 expression is temporospatially regulated in the developing mouse embryo,
with strong expression in developing skeletal muscle, was highly suggestive evidence that
fueled these present studies. We have since found Rgs12 expressed in mouse adult TA muscle,
and its expression increased following injury and in dystrophic muscle, further suggesting a
role for RGS12 in muscle regeneration. The dynamic regulation of Rgs12 mRNA expression
seen in muscle precursor cells during myogenesis is consistent with a potential role for the
encoded G protein- and MAPK-scaffold in coordinating myogenic signals: Rgs12 is expressed
in satellite cells and proliferating myoblasts, and reduced as myoblasts undergo differentiation
and fusion into myotubes. Moreover, RGS12 protein is seen to bind to endosomally enriched
phosphoinositides in vitro and to be localized to early endosomes in cultured myoblasts, sug-
gesting that its scaffolding properties [7] may localize specific molecular interactions (i.e., Ras/
Raf/MEK/ERK signaling cascade components) to certain cytosolic sub-regions within the acti-
vated satellite cell itself, the trans-amplifying cell destined for differentiation, or both.
We demonstrate here that ectopically expressed, oncogenic (G12V) H-Ras associates with
(and stabilizes the levels of) RGS12 in transfected C2C12 cells. These observations are consis-
tent with prior demonstrations of an association of RGS12 with activated but not wild-type
H-Ras [7]; yet, on their own, they do not establish causality for the known or suspected func-
tions of either protein. The inhibition of myotube formation seen upon activated H-Ras
expression [24–26] (Fig 3) likely arises from a pleotropy of signaling consequences down-
stream of multiple H-Ras effectors [77] in addition to, or even exclusive of, RGS12 function as
an H-Ras/Raf/MEK2 scaffold [7]. Moreover, the stabilization of endogenous RGS12 levels
upon activated H-Ras over-expression may be an effect, rather than the cause, of an inhibited
differentiation program. The inhibition of C2C12 myotube formation seen upon Rgs12 knock-
down and enhanced formation upon ectopic RGS12 over-expression, while seemingly contra-
dictory to the stabilized RGS12 levels seen in the poorly differentiating C2HRas cell line, are
both likely to be artificial outcomes of the “combinatorial inhibition” phenomenon commonly
observed with signaling scaffolds [78, 79], as we have previously denoted in explaining biphasic
effects of RGS12 expression in studies of receptor-initiated ERK activation [7].
Our present in vitro analyses demonstrate that RGS12 over-expression in myoblasts
represses proliferation and promotes differentiation, suggesting that RGS12 may normally act
to coordinate GTPase and/or MAPK signals downstream of pro-differentiation and/or pro-
fusion external input(s) (perhaps via Wnt-liganded and/or BAI3 GPCR activation(s); refs. [80,
81]) and thereby impact on the terminal differentiation of myoblasts, similar to how RGS12
(and the related RGS14) is thought to act in neuronal axonogenesis driven by NGF and bFGF
signaling [7, 37]. Consistent with the in vitro findings, delayed muscle regeneration was
observed in mice conditionally deficient in Rgs12 expression in Pax7+ satellite cells; however,
muscle repair returned to normal by 24 days post-injury. When tissue-restricted Rgs12 loss
was cross-bred into the mdx mouse model of Duchenne muscular dystrophy, no change in the
dystrophic phenotype was observed over time. Collectively, these data support the hypothesis
that RGS12 plays a role in coordinating signals during myogenic programming, but its loss
can be compensated for over time and in models of repeated muscle damage and repair. Given
that RGS proteins are generally considered “regulators” of the potency and amplitude of recep-
tor-initiated intracellular signaling (e.g., refs. [82, 83]), rather than obligate components
thereof, the most likely mechanism of such compensation is achievement of a particular
threshold of accumulated signal over time in the absence of RGS12’s regulatory influence. Fur-
ther elucidating both time- and tissue-restricted loss of RGS12 in adult skeletal muscle satellite
cells should provide improved resolution as to the in vivo role(s) of RGS12 in myogenic signal-
ing. For example, a further test for a specific role of RGS12 in muscle wasting could entail stud-
ies of muscle progenitor phenotype and function with Utrntm1Ked; Dmdmdx; Rgs12-deficient
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mice. Utrophin (Utrn), a cytoskeletal protein highly related to dystrophin, is thought to com-
pensate for dystrophin loss in the spontaneous mdx mouse model of DMD. While utrophin-
deficient mice are healthy and generally show no signs of weakness [84], utrophin/dystrophin-
deficient mice exhibit a more severe dystrophic phenotype than single Dmdmdx mutant mice
[85]: i.e., the double knockout strain exhibits a phenotype that more closely resembles DMD in
humans with severe progressive muscular dystrophy resulting in premature death. Recent evi-
dence [86] suggests that this accelerated disease progression is associated with a more rapid
decrease in the number and regenerative potential of muscle progenitor cells; these results
highlight the notion that alleviating progenitor cell depletion could delay the onset of histopa-
thology seen in DMD patients [86]. Our hope is that future findings as to the role(s) of RGS12
in muscle repair and muscle wasting could inform novel therapeutic strategies for DMD and
other muscular dystrophies.
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